Topics:

Thyroid Cancer

Thyroid Cancer

Tumor growth rate analysis may be a valuable efficacy parameter to consider in patients with sorafenib-treated, radioiodine-refractory differentiated thyroid cancer.

A small Greek case-control study found that drinking herbal teas, and in particular chamomile tea, over a long period of time is linked to a decreased risk of developing thyroid cancer and other thyroid diseases.

The multi-targeted TKI lenvatinib showed promise in a phase II trial of patients with advanced, radioiodine-refractory, differentiated thyroid cancer.

A new population-based study has found that patients with thyroid cancer who are treated with radioactive iodine therapy are at increased risk for developing salivary cancer as a second malignancy.

A recent study found that women diagnosed with breast cancer are at increased risk for developing thyroid cancer, prompting the authors to encourage regular screening for the disease in breast cancer survivors.

Despite well-established guidelines from the American Thyroid Association, radioactive iodine continues to be overused for some forms of thyroid cancer.

The FDA has approved lenvatinib (Lenvima) for the treatment of patients with progressive, differentiated thyroid cancer refractory to radioactive iodine.

Pages

Subscribe to Thyroid Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.